UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

UroGen Pharma granted up to 117,100 inducement RSU-based shares to 19 new hires, vesting over three years under its 2019 Inducement Plan.

Rhea-AI Summary

UroGen Pharma (URGN) granted inducement restricted stock units (RSUs) to 19 new employees on September 4, 2026, under Nasdaq Listing Rule 5635(c)(4).

Up to 117,100 ordinary shares are issuable upon vesting, which occurs in three equal annual installments over three years, subject to continued service and the company’s 2019 Inducement Plan.

Market Context

URGN's August 20 partnership announcement was followed by a -6.94% 24-hour reaction, while August 5 ...

Analysis

URGN's August 20 partnership announcement was followed by a -6.94% 24-hour reaction, while August 5 earnings produced +16.31%. This record frames the equity-award disclosure against mixed event sensitivity; insider Net Selling remains a risk to monitor.

Key Figures

New employees: 19 employees Shares issuable: Up to 117,100 ordinary shares Vesting period: Three years +1 more

4 metrics

New employees 19 employees Inducement RSU grants

Shares issuable Up to 117,100 ordinary shares Upon RSU vesting and settlement

Vesting period Three years Equal annual vesting schedule

Annual vesting One-third of underlying shares Each year on the vesting anniversary

Historical Context

5 past events · Latest: Sep 02 (Neutral)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Sep 02	Investor conferences	Neutral	+2.5%	Scheduled September fireside chats at three healthcare-focused investor conferences.
Aug 20	Strategic partnership	Positive	-6.9%	Collaboration and investment agreement provided access to IntraGel's oncology platform.
Aug 20	Strategic partnership	Positive	-6.9%	UroGen obtained options for TumoCure and additional sustained-release oncology products.
Aug 17	NDA submission	Positive	+1.9%	UroGen submitted an NDA for investigational treatment UGN-103.
Aug 05	Q2 earnings	Positive	+16.3%	Revenue growth and improved net loss accompanied second-quarter financial results.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

UroGen's prior positive announcements generally produced gains, while both August 20 partnership reports were followed by declines.

Key Terms

restricted stock units, Nasdaq Listing Rule 5635(c)(4)

2 terms

restricted stock units financial

"announced the grants of inducement restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Nasdaq Listing Rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

PRINCETON, N.J., Sept. 04, 2026 (GLOBE NEWSWIRE) -- UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced the grants of inducement restricted stock units (“RSUs”) to 19 new employees in connection with their employment with UroGen. These new team members will support the ongoing commercialization of JELMYTO^® (mitomycin) for pyelocalyceal solution and ZUSDURI™ (mitomycin) for intravesical solution, UroGen’s only approved products, and the continued development of UroGen’s pipeline.

Up to 117,100 ordinary shares of UroGen are issuable upon the vesting and settlement of the RSUs. The RSUs will vest equally over three years, with one-third of the underlying shares vesting each year on the anniversary of the vesting date, subject in each case to the employee’s continued service relationship with UroGen.

The RSUs are subject to the terms and conditions of UroGen’s 2019 Inducement Plan and RSU grant notice and agreement thereunder. The RSUs were granted as an inducement material to each employee entering into employment with UroGen in accordance with Nasdaq Listing Rule 5635(c)(4).

About UroGen Pharma Ltd.
UroGen is a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers because patients deserve better options. UroGen has developed RTGel^® reverse-thermal hydrogel, a proprietary sustained-release, hydrogel-based platform technology that has the potential to improve the therapeutic profiles of existing drugs. UroGen’s sustained release technology is designed to enable longer exposure of the urinary tract tissue to medications, making local therapy a potentially more effective treatment option. UroGen’s first commercial product is approved to treat low-grade upper tract urothelial cancer, and UroGen’s second product is the first and only FDA-approved medication for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. Both medicines are designed to ablate tumors by non-surgical means. UroGen is headquartered in Princeton, New Jersey with operations in Israel. To learn more, visit www.urogen.com or follow us on X, @UroGenPharma.

JELMYTO^®, RTGel^®, ZUSDURI™ and UroGen^® are registered trademarks of UroGen Pharma Ltd.

INVESTOR CONTACT:
Vincent Perrone
vincent.perrone@urogen.com
(609) 460-3588 Ext. 1093

MEDIA CONTACT:
Cindy Romano
Cindy.romano@urogen.com
(609) 460-3566 Ext. 1083

FAQ

What did UroGen Pharma (URGN) announce regarding inducement grants on September 4, 2026?

UroGen Pharma announced it granted inducement restricted stock units (RSUs) to 19 new employees. These equity awards were made as material inducements for joining the company, in accordance with Nasdaq Listing Rule 5635(c)(4), and are issued under UroGen’s 2019 Inducement Plan.

How many shares are covered by the new UroGen Pharma (URGN) inducement RSUs?

The inducement RSU grants cover up to 117,100 ordinary shares of UroGen Pharma. These shares will be issued only upon the vesting and settlement of the RSUs, subject to each employee’s continued service with the company and the terms of the 2019 Inducement Plan.

What is the vesting schedule for the new UroGen Pharma (URGN) inducement RSUs?

The RSUs vest in three equal installments over three years. One-third of the underlying shares vests each year on the anniversary of the vesting date, provided the employee maintains a continued service relationship with UroGen throughout the applicable vesting periods.

Under which plan were the UroGen Pharma (URGN) inducement RSUs granted?

The inducement RSUs were granted under UroGen Pharma’s 2019 Inducement Plan. Each award is governed by the plan’s terms and an RSU grant notice and agreement, which set the conditions for vesting, settlement, and continued service requirements for the participating employees.

Why were the new UroGen Pharma (URGN) RSUs classified as inducement grants under Nasdaq Rule 5635(c)(4)?

The RSUs were granted as inducement awards that were “material” to each employee entering into employment with UroGen. The company states these grants comply with Nasdaq Listing Rule 5635(c)(4), which permits equity awards to new hires outside shareholder-approved plans when used as hiring incentives.